New shot aims to cut dangerous COPD attacks
NCT ID NCT07418736
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental drug called CM326, given as a shot, in 318 people with moderate-to-severe COPD. The goal is to see if it can reduce the number of serious flare-ups over 24 to 52 weeks compared to a placebo. Participants must be at least 40 years old, have had COPD for over a year, and have had at least two flare-ups in the past.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CM326 (a lab-made antibody given as a shot)
What this could lead to
If it works, this could offer a new way to reduce serious COPD flare-ups and improve breathing for people with moderate-to-severe disease.
What could go wrong
This is an early Phase 2 trial, so results are not yet proven. The drug may not reduce flare-ups better than a placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China-Japan Friendship Hospital
RECRUITINGBeijing, Beijing Municipality, 100000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••